pka i

Rp-cAMPS triethylammonium salt 是 cAMP 依赖性蛋白激酶 I 和 II 的竞争性抑制剂，通过阻断 cAMP 诱导的构象转换来抑制 cAMP 诱导的 cAMP 依赖性蛋白激酶 （PKA） 激活。

PKA inhibitor fragment (6-22) amide Acetate 是一种通过结合底物位点选择性抑制PKA 活性的合成肽(IC50 < 2 nM)。

PKI PKA Inhibitor (5-24) is a synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) (Ki= 2.3 nM) derived from the active site of the skeletal muscle inhibitor protein.1It mimics the protein substrate by binding to the catalytic site through the arginine-cluster basic subsite.1The prominent enzyme-substrate interaction site occurs where PKA catalytic subunit residues Tyr235and Phe239form a sandwich-like structure with residue Phe10of PKI (5-24).2

PKA Inhibitor Fragment (6-22) amide TFA (PKA Inhibitor Fragment (6-22) amide TFA) 是抑制高效 cAMP 依赖性蛋白激酶 A (PKA)抑制剂(Ki：2.8 nM)。PKA Inhibitor Fragment (6-22) amide TFA 可逆转小鼠低水平的吗啡缓解疼痛的作用。

Rp-cAMPS 竞争性抑制 cAMP 诱导的 cAMP 依赖性蛋白激酶激活。

Rp-cAMPS sodium 是一种cAMP的硫代磷酸酯类似物，是一种蛋白激酶 A 抑制剂，也是具有膜渗透性的 cAMP 拮抗剂，通过阻断 cAMP 诱导的构象转变来抑制 cAMP 依赖性蛋白激酶，可用于研究心血管疾病。

PKA-IN-1 是一种具有选择性和有效性的 cyclic AMP 依赖性蛋白激酶 (PKA) 催化亚基 (cAK) 抑制剂（IC50 ： 0.03 μM）。PKA-IN-1 可用于研究免疫系统疾病。

Sp-cAMPS sodium salt 作为 cAMP 类似物，是一种依赖 cAMP 的PKA I 和PKA II 的有效激活剂。Sp-cAMPS sodium salt 还是一种有效的竞争性磷酸二酯酶 (PDE3A) 抑制剂，Ki 为 47.6 μM。Sp-cAMPS sodium salt 结合PDE10 GAF 结构域，EC50为 40 μM 。

Ellagic acid (Gallogen) 是一种稠合四环类天然产物，是一种有效的 CK2 抑制剂 (IC50=40 nM；Ki=20 nM)，具有 ATP 竞争性。Ellagic acid 是一种抗氧化剂，也具有抗增殖活性。

A-3 hydrochloride 是一种细胞可渗透的、可逆的、ATP 竞争性非选择性拮抗剂。它抑制 PKA 、酪蛋白激酶 II 和肌球蛋白轻链激酶，Ki 值分别为4.3 µM、5.1 µM 和7.4 µM。它还抑制 PKC 和酪蛋白激酶 I 的活性，Ki 分别为 47 µM 和 80 µM。

KT5823 是一种具有选择性和有效性的 cGMP 依赖性蛋白激酶 (PKG) 抑制剂，对 PKA 和 PKG 有抑制作用。KT5823 在甲状腺细胞中通过调节碘化钠交感蛋白的表达和活性来增加甲状腺刺激激素诱导的 (Na+ I- symporter) NIS 表达和碘离子摄取。 KT5823 诱导细胞凋亡。

Two Rho-associated kinases (ROCK), ROCK-I and ROCK-II, act downstream of the G protein Rho to regulate cytoskeletal stability. The ROCKs play important roles in diverse cellular functions including cell adhesion and proliferation, smooth muscle contraction, and stem cell renewal. Glycyl-H-1152 is a selective and potent ROCK inhibitor (IC50 = 11.8 nM for ROCK-II). It is a glycylated isoquinoline compound derived from the therapeutically-important ROCK inhibitor HA-1077 (Fasudil) and exhibits better specificity. Thus, it poorly inhibits Ca2+/calmodulin-dependent kinase type II, protein kinase (PK) G, and Aurora A (IC50 = 2.57, 2.35, and 3.26 μM, respectively) as well as PKA or PKC (IC50 ≥ 10 μM for each). The potency of Glycyl-H-1152 is superior to that of other ROCK inhibitors, including Y-27632 (Ki = 220 nM) and HA-1077 (IC50 = 158 nM).

Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP. It acts as an antagonist of cAMP-dependent protein kinases (PKAs) and is resistant to hydrolysis by cyclic nucleotide phosphodiesterases. Rp-8-bromo-cAMPS more effectively antagonizes cAMP-dependent activation of purified PKA type I from rabbit muscle than PKA type II from bovine heart.

Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP and Rp-cyclic AMPS .[1] It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, with preference towards site A of type I and site B of type II.2 By occupying cAMP binding sites at the regulatory subunit of PKA, Rp-8-CPT-cAMP prevents the kinase holoenzyme from dissociative activation.[2],[3]

Sp-8-CPT-cAMPS is a powerful and specific cAMP analog that activates cAMP-dependent protein kinase A (PKA I and PKA II) selectively and effectively. It exhibits a 153-fold preference for site A of RI over site A of RII, and a 59-fold preference for site B of RII over site B of RI.

Rp-8-CPT-cAMPS is a powerful and competitive antagonist of cAMP-induced activation of cAMP-dependent protein kinase (PKA) I and II. Acting as a potent cAMP analog, Rp-8-CPT-cAMPS exhibits a preference for site A of RI over site A of RII. Additionally, it favors site B of RII over site B of RI. This compound effectively inhibits cAMP-dependent PKA activation and demonstrates selectivity in binding to specific sites within the protein kinase.

Sp-cAMPS triethylamine，一种 cAMP 类似物，是一种依赖 cAMP 的PKAI 和PKAII 的有效激活剂。Sp-cAMPS triethylamine 还是一种有效的竞争性磷酸二酯酶 (PDE3A) 抑制剂，Ki 为 47.6 µM。Sp-cAMPS triethylamine 以EC50为 40 μM 来结合PDE10GAF 域。

PKI(5-24) TFA 是一种强效、竞争性、合成的PKA(cAMP 依赖性蛋白激酶) 抑制剂，Ki 为 2.3 nM。PKI(5-24) TFA 对应于天然存在的热稳定蛋白激酶抑制剂中的 5-24 残基。

PKI (5-24),amide (IP20-amide)为对应于cAMP依赖性蛋白激酶热稳定抑制蛋白活性部分的20残基肽。该化合物是一种高效的cAMP依赖性蛋白激酶(PKA)抑制剂，具有2.3 nM的Ki值。

Fasudil mesylate (HA-1077; AT877) 是一种口服有效的非特异性RhoA ROCK抑制剂，同时能够抑制多种蛋白激酶。该化合物对ROCK1的Ki值为0.33 μM，对ROCK2、PKA、PKC和PKG的IC50值分别为0.158 μM、4.58 μM、12.30 μM和1.650 μM。此外，Fasudil mesylate 还作为Ca2+通道拮抗剂和血管扩张剂，表现出良好的药效。

8-MA-cAMP（8-Methylamino-cAMP）是一种环磷酸腺苷类似物，充当位点选择性的PKA激动剂，对I型和II型蛋白激酶A的B位点具有相似的结合亲和性。此外, 8-MA-cAMP 结合显示位点A偏好的类似物如8-哌啶基cAMP，能够实现对I型PKA的选择性激活。

Sp-8-pCPT-cGMPS 是一种对CNG通道具有高激活作用的化合物(cyclic guanosine monophosphate-gated channel)，并且作为 PKG (I α、I β 和 II 型) 以及 PKA II 型的疏水性活化剂显示出色的细胞膜穿透能力和对磷酸二酯酶的高稳定性。此外，Sp-8-pCPT-cGMPS 还常用于探究 cGMP 在神经可塑性及突触功能中的调控机制。

AKAP disruptor. Selectively binds PKA-RI with high affinity (KD values are 6.2 and 12.1 nM for the RIα and β subunits, respectively) and blocks its interaction with AKAP. Inhibits type I PKA-mediated phosphorylation in live cells. Cell permeable.